Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08254320

Publication Date:

August 6, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Manufacturing (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

According to this study, the global Antibody-oligonucleotide Conjugates (AOCs) market size will reach US$ 586 million by 2031.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody鈥檚 ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE鈩� platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
The 鈥淎ntibody-oligonucleotide Conjugates (AOCs) Industry Forecast鈥� looks at past sales and reviews total world Antibody-oligonucleotide Conjugates (AOCs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-oligonucleotide Conjugates (AOCs) sales for 2025 through 2031. With Antibody-oligonucleotide Conjugates (AOCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-oligonucleotide Conjugates (AOCs) industry.
This Insight Report provides a comprehensive analysis of the global Antibody-oligonucleotide Conjugates (AOCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-oligonucleotide Conjugates (AOCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Antibody-oligonucleotide Conjugates (AOCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-oligonucleotide Conjugates (AOCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-oligonucleotide Conjugates (AOCs).
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-oligonucleotide Conjugates (AOCs) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Site-specific Coupling
Random Coupling
Segmentation by Application:
Rare and Genetic Diseases
Cancer Treatment
Central Nervous System Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size 2025-2031
2.1.2 Antibody-oligonucleotide Conjugates (AOCs) Market Size CAGR by Region
2.2 Antibody-oligonucleotide Conjugates (AOCs) Segment by Type
2.2.1 Site-specific Coupling
2.2.2 Random Coupling
2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
2.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2025-2031)
2.3.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (2025-2031)
2.4 Antibody-oligonucleotide Conjugates (AOCs) Segment by Application
2.4.1 Rare and Genetic Diseases
2.4.2 Cancer Treatment
2.4.3 Central Nervous System Disorders
2.5 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2025-2031)
2.5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2025-2031)
2.5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Application (2025-2031)
3 Antibody-oligonucleotide Conjugates (AOCs) Key Players
3.1 Date of Key Players Enter into Antibody-oligonucleotide Conjugates (AOCs)
3.2 Key Players Antibody-oligonucleotide Conjugates (AOCs) Product Offered
3.3 Key Players Antibody-oligonucleotide Conjugates (AOCs) Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Antibody-oligonucleotide Conjugates (AOCs) Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 Antibody-oligonucleotide Conjugates (AOCs) by Regions
4.1 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Regions (2025-2031)
4.2 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2025-2031)
4.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2025-2031)
4.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2025-2031)
4.5 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2025-2031)
5 United States
5.1 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2025-2031)
5.2 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2025-2031)
6 Europe
6.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2025-2031)
6.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2025-2031)
7 China
7.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2025-2031)
7.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2025-2031)
8 Rest of World
8.1 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2025-2031)
8.2 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2025-2031)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Key Investors in Antibody-oligonucleotide Conjugates (AOCs)
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 鈥︹€�
11 Key Players Analysis
11.1 Avidity Biosciences
11.1.1 Avidity Biosciences Company Details
11.1.2 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.1.4 Avidity Biosciences Main Business Overview
11.1.5 Avidity Biosciences News
11.2 Dyne Therapeutics
11.2.1 Dyne Therapeutics Company Details
11.2.2 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.2.4 Dyne Therapeutics Main Business Overview
11.2.5 Dyne Therapeutics News
11.3 Tallac Therapeutics
11.3.1 Tallac Therapeutics Company Details
11.3.2 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.3.4 Tallac Therapeutics Main Business Overview
11.3.5 Tallac Therapeutics News
11.4 Denali Therapeutics
11.4.1 Denali Therapeutics Company Details
11.4.2 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.4.4 Denali Therapeutics Main Business Overview
11.4.5 Denali Therapeutics News
11.5 Gennao Bio
11.5.1 Gennao Bio Company Details
11.5.2 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.5.4 Gennao Bio Main Business Overview
11.5.5 Gennao Bio News
11.6 ChainGen Bio
11.6.1 ChainGen Bio Company Details
11.6.2 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product Offered
11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2024 VS 2030)
11.6.4 ChainGen Bio Main Business Overview
11.6.5 ChainGen Bio News
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂